AdvanSix vs Eastman Chemical
ASIX and EMN side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASIX and EMN compare
Eastman Chemical is the larger company, worth 18 times as much as AdvanSix ($7.4B against $423M).
AdvanSix grew revenue faster over the last twelve months (8.4% versus 0.27% for Eastman Chemical).
Eastman Chemical keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with −1.4% at AdvanSix.
Both pay dividends: AdvanSix yields 4.1% and Eastman Chemical 5.2%.
Eastman Chemical scores higher on the StockData Score (16 against 10 for AdvanSix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASIX | EMN |
|---|---|---|
| Size and price | ||
| Market cap | $423M | $7.4B |
| Share price | $15.68 | $65.03 |
| Change, 1 year | −3.0% | 6.7% |
| Change, 5 years | −67.4% | −42.5% |
| Beta (5Y) | 0.94 | 1.10 |
| Employees | 1,410 | 13K |
| StockData Score | ||
| Total score | 10 | 16 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 2 | 6 (better) |
| Valuation | ||
| P/E | – | 12.0× |
| P/S | 0.3× (better) | 0.8× |
| P/B | 0.5× (better) | 1.2× |
| P/FCF | 109× | 15.9× (better) |
| FCF yield | 0.91% | 6.3% (better) |
| Fair value | $34.90 | $92.79 |
| Margin of safety | 55.1% (better) | 29.9% |
| Growth | ||
| Revenue growth (TTM) | 8.4% (better) | 0.27% |
| Revenue growth, 5Y average | 5.6% (better) | 0.65% |
| Net income growth (TTM) | −143% | −13.3% (better) |
| EPS growth (TTM) | −144% | −12.3% (better) |
| EPS growth, 5Y average | 1.9% | 3.2% (better) |
| Profitability | ||
| Gross margin | 4.5% | 20.6% (better) |
| Net margin | −1.4% | 6.9% (better) |
| FCF margin | 0.24% | 5.2% (better) |
| Return on equity | −2.8% | 10.4% (better) |
| Financial health | ||
| Debt / equity | 0.34 (better) | 0.83 |
| Current ratio | 1.20 | 1.57 (better) |
| Altman Z-score | 1.82 | 2.13 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 4.1% | 5.2% (better) |
| Payout ratio | – | 61.1% |
| Years of dividend growth | – | 16 |
| Dividend growth, 5Y average | – | 4.5% |
| Buyback yield | 0.30% | – |
| Shareholder yield | 4.4% | 5.2% (better) |
| Ownership | ||
| Held by institutions | 91.7% | 94.1% |
| Held by insiders | 4.6% | 0.83% |
| Insider net buying, 12 months | – | −$206K |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.1% | 4.9% |
Go deeper
- ASIX stock overview
- ASIX income statement
- ASIX valuation and score
- EMN stock overview
- EMN income statement
- EMN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.